Abstract
The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Current Diabetes Reviews
Title:Prediction and Diagnosis of Post Transplant Diabetes
Volume: 11 Issue: 3
Author(s): Christopher J. Yates and Solomon J. Cohney
Affiliation:
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Abstract: The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Export Options
About this article
Cite this article as:
Yates J. Christopher and Cohney J. Solomon, Prediction and Diagnosis of Post Transplant Diabetes, Current Diabetes Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573399811999150316105553
DOI https://dx.doi.org/10.2174/1573399811999150316105553 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sleep-Related Disorders, Diabetes and Obesity: Understanding the Facts
Current Respiratory Medicine Reviews Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Angiotensin I-Converting Enzyme: A Pathogenetic Role in Diabetic Renal Damage?
Current Diabetes Reviews Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Targeting TRPs in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Nanoemulsions for Intranasal Delivery of Riluzole to Improve Brain Bioavailability: Formulation Development and Pharmacokinetic Studies
Current Drug Delivery Biomarkers for Alzheimer’s Disease
Current Alzheimer Research Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms
Current Cardiology Reviews Potential Drugs and Methods for Preventing or Delaying the Progression of Huntington's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Mechanisms of Neuroprotection by Polyphenols
Current Medicinal Chemistry - Central Nervous System Agents Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Current Gene Therapy Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders
Current Protein & Peptide Science Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine